2025 AI Stock Picks: 2 Hidden Gems Under $10/Share

The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.

👉[Click here to get your FREE report delivered instantly!]

SYRS Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 12.26%

Insider Buying (Last 12 Months): $4,206,488.91

Insider Selling (Last 12 Months): $203,946.09

Syros Pharmaceuticals Insider Trading History Chart

Syros Pharmaceuticals Share Price & Price History

^$0.27

▼ -0.02 (-6.90%)

As of 11/21/2024 01:00 AM ET

Days: 30 | 90 | 365

Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out?

From Golden Crest | Ad

Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too?

Click Here For Your Free Guide

Syros Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/12/2024	Jason Haas	CFO	Buy	45,344	$1.68	$76,177.92	124,552
9/10/2024	Conley Chee	CEO	Buy	50,000	$1.51	$75,500.00	72,504
9/10/2024	Jason Haas	CFO	Buy	35,363	$1.55	$54,812.65	59,915
6/28/2024	Richard A Young	Director	Sell	34,837	$5.12	$178,365.44	8,000
4/2/2024	David Roth	Insider	Sell	150	$4.98	$747.00	10,451
12/21/2023	Srinivas Akkaraju	Director	Buy	904,977	$4.42	$3,999,998.34	1,786,427
12/6/2023	David Roth	Insider	Sell	6,287	$3.95	$24,833.65	6,287
7/31/2023	David Roth	Insider	Sell	7,348	$3.95	$29,024.60
7/17/2023	Eric R. Olson	Insider	Sell	689	$3.50	$2,411.50	6,661
9/29/2022	Timothy Tyson	Director	Buy	2,932	$5.72	$16,771.04	10,932
1/5/2022	Eric R. Olson	Insider	Sell	2,208	$3.47	$7,661.76

I've got news for you…

From DTI | Ad

Today, I’m doing something I thought I’d never do… Especially since I’m not normally a “swing for the fences” type of trader. But I’ve been quietly testing a new type of trade for a while now… And the returns are too good not to share with you. Take a look… I can’t guarantee results or against losses, but if you want to discover how I’ll target the triple return before the end of the week

watch this FREE briefing with me and expert trader Graham Lindman

SEC Filings (Institutional Ownership Changes) for Syros Pharmaceuticals (NASDAQ:SYRS)

91.47% of Syros Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Syros Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/14/2024	Walleye Capital LLC	86,641	$0.19M	0.0%	-69.7%	0.323%
11/5/2024	GSA Capital Partners LLP	15,905	$34K	0.0%	N/A	0.059%
8/9/2024	Renaissance Technologies LLC	117,435	$0.61M	0.0%	-2.0%	0.438%
8/6/2024	Certuity LLC	21,202	$0.11M	0.0%	N/A	0.079%
8/6/2024	Acadian Asset Management LLC	34,578	$0.18M	0.0%	+101.5%	0.129%
7/18/2024	Assenagon Asset Management S.A.	15,873	$82K	0.0%	-90.7%	0.059%
5/29/2024	Opaleye Management Inc.	787,545	$4.21M	0.9%	+119.1%	2.947%
5/20/2024	Virtu Financial LLC	12,030	$64K	0.0%	N/A	0.045%
5/16/2024	Kennedy Capital Management LLC	404,914	$2.17M	0.0%	N/A	1.515%
5/10/2024	Acadian Asset Management LLC	17,162	$91K	0.0%	N/A	0.064%
5/10/2024	Vanguard Group Inc.	928,046	$4.97M	0.0%	+21.3%	3.472%
4/24/2024	Assenagon Asset Management S.A.	169,999	$0.91M	0.0%	+576.5%	0.636%
2/15/2024	Opaleye Management Inc.	359,370	$2.80M	0.7%	N/A	1.706%
2/15/2024	Flagship Pioneering Inc.	1,293,848	$10.08M	0.8%	+30.2%	6.141%
2/14/2024	Avidity Partners Management LP	1,673,538	$13.04M	0.5%	+5.8%	7.943%
2/13/2024	Bain Capital Life Sciences Investors LLC	2,749,808	$21.42M	2.1%	+29.4%	13.051%
11/14/2023	Avidity Partners Management LP	1,581,142	$6.25M	0.3%	+8.0%	7.635%
11/13/2023	CHI Advisors LLC	1,299,359	$5.12M	1.5%	+69.3%	6.274%
11/6/2023	Assenagon Asset Management S.A.	25,130	$99K	0.0%	+142.2%	0.121%
10/19/2023	Clarius Group LLC	18,620	$74K	0.0%	N/A	0.090%
8/14/2023	Shay Capital LLC	26,426	$83K	0.0%	+87.3%	0.128%
8/11/2023	ExodusPoint Capital Management LP	118,398	$0.37M	0.0%	-2.6%	0.572%
5/16/2023	Ally Bridge Group NY LLC	249,126	$0.67M	0.9%	-71.3%	1.210%
5/11/2023	CHI Advisors LLC	767,445	$2.05M	0.5%	N/A	3.760%
4/18/2023	Assenagon Asset Management S.A.	10,376	$28K	0.0%	N/A	0.051%
2/9/2023	Denali Advisors LLC	7,700	$28K	0.0%	N/A	0.038%
11/15/2022	Flagship Pioneering Inc.	993,848	$6.40M	0.3%	-66.2%	15.775%
11/15/2022	Bain Capital Life Sciences Investors LLC	1,082,404	$6.97M	0.8%	-82.7%	17.181%
11/9/2022	Edmond DE Rothschild Holding S.A.	4,382	$28K	0.0%	N/A	0.070%
10/24/2022	Clarius Group LLC	19,347	$0.13M	0.0%	-90.0%	0.307%
10/13/2022	LGT Capital Partners LTD.	55,000	$0.35M	0.0%	-90.0%	0.873%
8/11/2022	Artal Group S.A.	4,000,000	$3.85M	0.2%	+14.3%	6.367%
8/10/2022	Clarius Group LLC	193,483	$0.19M	0.0%	N/A	0.308%
7/19/2022	Sawtooth Solutions LLC	42,286	$41K	0.0%	+76.5%	0.067%
7/13/2022	LGT Capital Partners LTD.	550,000	$0.53M	0.0%	+10.0%	0.876%
7/13/2022	Private Advisor Group LLC	51,437	$50K	0.0%	+112.9%	0.082%
5/16/2022	Ally Bridge Group NY LLC	3,364,895	$4M	3.0%	-4.9%	5.420%
5/12/2022	Artal Group S.A.	3,500,000	$4.17M	0.2%	+16.7%	5.638%
5/12/2022	Connor Clark & Lunn Investment Management Ltd.	137,156	$0.16M	0.0%	+15.6%	0.221%
5/11/2022	ACT Capital Management LLC	35,000	$42K	0.0%	+62.8%	0.056%
5/11/2022	GSA Capital Partners LLP	372,208	$0.44M	0.1%	+53.7%	0.600%
2/15/2022	Adage Capital Partners GP L.L.C.	1,900,000	$6.19M	0.0%	+5.6%	3.067%
2/14/2022	Altium Capital Management LP	1,160,000	$3.78M	1.0%	-8.8%	1.873%
2/14/2022	GSA Capital Partners LLP	242,132	$0.79M	0.1%	+119.4%	0.391%
2/14/2022	Ally Bridge Group NY LLC	3,539,895	$11.54M	4.0%	+2.9%	5.714%
2/11/2022	Ensign Peak Advisors Inc	45,000	$0.15M	0.0%	-55.0%	0.073%
2/10/2022	Connor Clark & Lunn Investment Management Ltd.	118,632	$0.39M	0.0%	+14.8%	0.192%
2/7/2022	SG Americas Securities LLC	12,012	$39K	0.0%	-61.4%	0.019%
2/3/2022	ACT Capital Management LLC	21,500	$70K	0.1%	-59.0%	0.035%
1/14/2022	LGT Capital Partners LTD.	500,000	$1.63M	0.0%	+1,052.4%	0.807%
11/17/2021	Altium Capital Management LP	1,272,412	$5.69M	1.3%	+18.2%	2.054%
11/16/2021	Two Sigma Advisers LP	172,700	$0.77M	0.0%	-32.6%	0.279%
11/16/2021	Two Sigma Investments LP	91,278	$0.41M	0.0%	-24.2%	0.147%
11/16/2021	Metropolitan Life Insurance Co NY	16,415	$73K	0.0%	N/A	0.026%
11/15/2021	Point72 Hong Kong Ltd	7,062	$32K	0.0%	+168.8%	0.011%
11/15/2021	Cubist Systematic Strategies LLC	86,990	$0.39M	0.0%	-66.3%	0.140%
11/15/2021	Marshall Wace LLP	183,451	$0.82M	0.0%	-38.1%	0.296%
11/15/2021	Franklin Resources Inc.	64,000	$0.29M	0.0%	N/A	0.103%
11/15/2021	GSA Capital Partners LLP	110,337	$0.49M	0.1%	-21.7%	0.178%
11/12/2021	Trexquant Investment LP	30,162	$0.14M	0.0%	-10.4%	0.049%
11/12/2021	Geode Capital Management LLC	857,646	$3.83M	0.0%	-11.3%	1.384%
11/12/2021	Artal Group S.A.	2,000,000	$8.94M	0.2%	+17.6%	3.229%
11/12/2021	Connor Clark & Lunn Investment Management Ltd.	103,307	$0.46M	0.0%	+35.8%	0.167%
11/10/2021	Goldman Sachs Group Inc.	490,501	$2.19M	0.0%	-2.1%	0.792%
11/10/2021	Citigroup Inc.	9,702	$43K	0.0%	+49.5%	0.016%
11/9/2021	Barclays PLC	44,863	$0.20M	0.0%	-23.7%	0.072%
11/9/2021	BlackRock Inc.	4,353,672	$19.46M	0.0%	-2.5%	7.030%
11/9/2021	Ieq Capital LLC	27,800	$0.12M	0.0%	N/A	0.045%
11/8/2021	Summit Global Investments	31,800	$0.14M	0.0%	N/A	0.051%
11/8/2021	State Board of Administration of Florida Retirement System	78,535	$0.35M	0.0%	+233.0%	0.127%
11/8/2021	Russell Investments Group Ltd.	10,289	$45K	0.0%	-49.4%	0.017%
11/8/2021	Los Angeles Capital Management LLC	258,938	$1.16M	0.0%	-4.6%	0.418%
11/4/2021	Deutsche Bank AG	59,973	$0.27M	0.0%	+65.9%	0.097%
11/1/2021	SG Americas Securities LLC	31,096	$0.14M	0.0%	N/A	0.050%
10/19/2021	Assenagon Asset Management S.A.	87,073	$0.39M	0.0%	-24.8%	0.141%
10/13/2021	LGT Capital Partners LTD.	43,388	$0.19M	0.0%	N/A	0.070%
9/3/2021	Parametric Portfolio Associates LLC	19,110	$0.10M	0.0%	N/A	0.031%
8/25/2021	Marshall Wace LLP	296,405	$1.62M	0.0%	N/A	0.479%
8/17/2021	Millennium Management LLC	557,713	$3.04M	0.0%	+230.4%	0.901%
8/17/2021	Caas Capital Management LP	13,905	$76K	0.0%	N/A	0.022%
8/16/2021	PDT Partners LLC	116,801	$0.64M	0.0%	-20.8%	0.189%
8/16/2021	Cubist Systematic Strategies LLC	257,997	$1.41M	0.0%	+891.3%	0.417%
8/16/2021	Redmile Group LLC	38,912	$0.21M	0.0%	-81.7%	0.063%
8/16/2021	California State Teachers Retirement System	79,478	$0.43M	0.0%	+11.7%	0.128%
8/16/2021	Charles Schwab Investment Management Inc.	391,798	$2.14M	0.0%	+7.9%	0.633%
8/16/2021	State Street Corp	999,254	$5.45M	0.0%	+25.6%	1.613%
8/16/2021	Nuveen Asset Management LLC	180,514	$0.98M	0.0%	+23.1%	0.291%
8/16/2021	Omega Fund Management LLC	2,274,831	$12.40M	2.1%	+45.6%	3.673%
8/16/2021	Goldman Sachs Group Inc.	501,221	$2.73M	0.0%	-21.3%	0.809%
8/16/2021	Marshall Wace LLP	296,405	$1.62M	0.0%	N/A	0.479%
8/13/2021	Northern Trust Corp	554,422	$3.02M	0.0%	+6.6%	0.895%
8/13/2021	Altium Capital Management LP	1,076,942	$5.87M	1.4%	+750.0%	1.739%
8/13/2021	LPL Financial LLC	38,090	$0.21M	0.0%	+97.1%	0.062%
8/13/2021	Qube Research & Technologies Ltd	78,774	$0.43M	0.0%	+115.9%	0.127%
8/13/2021	Geode Capital Management LLC	966,448	$5.27M	0.0%	+16.0%	1.561%
8/13/2021	Vanguard Group Inc.	2,775,576	$15.13M	0.0%	+1.6%	4.482%
8/13/2021	FMR LLC	9,047,965	$49.31M	0.0%	+0.4%	14.610%
8/13/2021	ProShare Advisors LLC	26,050	$0.14M	0.0%	+23.3%	0.042%
8/12/2021	Trexquant Investment LP	33,676	$0.18M	0.0%	+97.8%	0.054%
8/12/2021	XTX Topco Ltd	26,018	$0.14M	0.0%	+132.9%	0.042%

Data available starting January 2016

Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $0.27

$0.26

$0.29

50 Day Range

MA: $1.91

$0.20

$3.23

52 Week Range

Now: $0.27

$0.18

$8.17

Volume

5,017,311 shs

Average Volume

2,333,590 shs

Market Capitalization

$7.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59

Who are the company insiders with the largest holdings of Syros Pharmaceuticals?: Syros Pharmaceuticals' top insider shareholders include:
Srinivas Akkaraju (Director)
Jason Haas (CFO)
Conley Chee (CEO)
David Roth (Insider)
Richard A Young (Director)
Eric R Olson (Insider)
Learn More about top insider investors at Syros Pharmaceuticals.
Who are the major institutional investors of Syros Pharmaceuticals?: Syros Pharmaceuticals' top institutional shareholders include:
Walleye Capital LLC — 0.32%
GSA Capital Partners LLP — 0.06%
Learn More about top institutional investors of Syros Pharmaceuticals stock.
Which major investors are selling Syros Pharmaceuticals stock?: During the previous quarter, SYRS stock was sold by these institutional investors:
Walleye Capital LLC
In the last year, company insiders that have sold Syros Pharmaceuticals company stock include:
Srinivas Akkaraju (Director)
Jason Haas (CFO)
Learn More investors selling Syros Pharmaceuticals stock.
Which major investors are buying Syros Pharmaceuticals stock?: In the previous quarter, SYRS stock was bought by institutional investors including:
GSA Capital Partners LLP
During the previous year, these company insiders have bought Syros Pharmaceuticals stock:
Srinivas Akkaraju (Director)
Jason Haas (CFO)
Conley Chee (CEO)
Learn More investors buying Syros Pharmaceuticals stock.